Latest News Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress. Jul 12 2024 Latest News Senhwa Biosciences Announces IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors. Jul 11 2024 Latest News Senhwa Biosciences Announces Jason Huang, MD as New Chief Medical Officer May 13 2024 Media Coverage AACR 2024 Annual Meeting-Visit Senhwa Biosciences Exhibit Booth Apr 03 2024 Media Coverage Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19 Nov 09 2023 Media Coverage Senhwa Biosciences Announces IND Submission to US FDA for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection Oct 19 2023 Publications Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Sep 24 2022 Publications Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 Publications Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic Dec 17 2020